Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Peking University First Hospital currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and 3 distinct art units, showing a relatively broad distribution of review for the portfolio. This distribution suggests that the hospital is pursuing multiple distinct innovations within the biotech field. For a practitioner, this variety is beneficial as it prevents the entire portfolio's progress from being dependent on a single examiner's perspective or the specific practices of one art unit, providing a more resilient prosecution strategy.
MCGUIRK, JOHN SCHUYLER is the busiest examiner, overseeing 1 busiest examiner pending action. This indicates that the 4 pending office actions are evenly distributed, with each of the 4 distinct examiners responsible for a single action. This balanced workload across multiple examiners and 3 distinct art units allows the hospital to navigate the patent office through several channels simultaneously. Each of the 4 pending office actions can be managed with a tailored approach, responding to the specific technical and legal concerns raised by each individual examiner to maximize the chances of allowance across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCGUIRK, JOHN SCHUYLER | 1 | 77.8% | +49.3% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| SCHULTZHAUS, JANNA NICOLE | 1 | 35.4% | +38.2% |
| MINCHELLA, KAITLYN L | 1 | 26.4% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273213 | GENE COMBINATION FOR HUMAN TUMOR GRADING, AND USE THEREOF | SALMON, KATHERINE D | — |
| 17755721 | METHOD AND DEVICE FOR CLASSIFICATION OF URINE SEDIMENT GENOMIC DNA, AND USE OF URINE SEDIMENT GENOMIC DNA | SCHULTZHAUS, JANNA NICOLE | — |
| 17609036 | cfDNA CLASSIFICATION METHOD, APPARATUS AND APPLICATION | MINCHELLA, KAITLYN L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412482 | LATERAL FLOW IMMUNOASSAY DEVICE FOR ALBUMIN DETECTION | MCGUIRK, JOHN SCHUYLER | — |
| 18273213 | GENE COMBINATION FOR HUMAN TUMOR GRADING, AND USE THEREOF | SALMON, KATHERINE D | — |
| 17755721 | METHOD AND DEVICE FOR CLASSIFICATION OF URINE SEDIMENT GENOMIC DNA, AND USE OF URINE SEDIMENT GENOMIC DNA | SCHULTZHAUS, JANNA NICOLE | — |
| 17609036 | cfDNA CLASSIFICATION METHOD, APPARATUS AND APPLICATION | MINCHELLA, KAITLYN L | — |
| Art Unit | Apps |
|---|---|
| 1685 | 2 |
| 1798 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18412482 | LATERAL FLOW IMMUNOASSAY DEVICE FOR ALBUMIN DETECTION | MCGUIRK, JOHN SCHUYLER | 1798 | §112 | Non-Final OA | — | Pending | Jan 13, 2024 |
| 18273213 | GENE COMBINATION FOR HUMAN TUMOR GRADING, AND USE THEREOF | SALMON, KATHERINE D | 1682 | §101 | Final Rejection | — | Pending | Jul 19, 2023 |
| 17755721 | METHOD AND DEVICE FOR CLASSIFICATION OF URINE SEDIMENT GENOMIC DNA, AND USE OF URINE SEDIMENT GENOMIC DNA | SCHULTZHAUS, JANNA NICOLE | 1685 | §101§103§112 | Final Rejection | — | Pending | Nov 21, 2022 |
| 17609036 | cfDNA CLASSIFICATION METHOD, APPARATUS AND APPLICATION | MINCHELLA, KAITLYN L | 1685 | §101§112 | Final Rejection | — | Pending | Apr 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeking University First Hospital has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
John Schuyler Mcguirk has the most, with 1 of Peking University First Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
